| Higher seroprevalence of anti-adeno-associated viral vector neutralizing antibodies among racial minorities in the United States A Khatri, R Shelke, S Guan, S Somanathan Human Gene Therapy 33 (7-8), 442-450, 2022 | 18 | 2022 |
| Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations H Soares, ML Baniecki, R Cardin, H Leister-Tebbe, Y Zhu, S Guan, ... | 12 | 2022 |
| Relationship between paraoxonase-1 genotype, activity, and major adverse cardiovascular events in patients with rheumatoid arthritis receiving tofacitinib C Charles-Schoeman, C Hyde, S Guan, N Parikh, J Wang, A Shahbazian, ... ARTHRITIS & RHEUMATOLOGY 72, 2020 | 4 | 2020 |
| Variable selection in varying multi-index coefficient models with applications to gene-environmental interactions S Guan Michigan State University. Statistics, 2017 | 2 | 2017 |
| In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance Y Zhu, I Yurgelonis, S Noell, Q Yang, S Guan, Z Li, L Hao, H Rothan, ... Science advances 10 (30), eadl4013, 2024 | 1 | 2024 |
| AB0511 A PHASE 1, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-AND MULTIPLE-DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF … S Cohen, J Beebe, V Chindalore, S Guan, M Hassan-Zahraee, C Hyde, ... Annals of the Rheumatic Diseases 82 (Suppl 1), 1450-1450, 2023 | 1 | 2023 |
| Relationship Between Paraoxonase-1 Genotype, Activity, and Malignancies in Patients with RA Receiving Tofacitinib C Charles-Schoeman, C Hyde, S Guan, N Parikh, J Wang, A Shahbazian, ... ARTHRITIS & RHEUMATOLOGY 73, 2050-2052, 2021 | 1 | 2021 |
| POS0442 RELATIONSHIP BETWEEN PARAOXONASE-1 GENOTYPE, ACTIVITY AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB C Charles-Schoeman, C Hyde, S Guan, N Parikh, J Wang, A Shahbazian, ... Annals of the Rheumatic Diseases 80 (Suppl 1), 449-450, 2021 | 1 | 2021 |
| A Phase 1, randomized, double-blind, placebo-controlled, single-and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375 … S Cohen, JS Beebe, V Chindalore, S Guan, M Hassan-Zahraee, ... Arthritis Research & Therapy 26 (1), 1-18, 2024 | | 2024 |
| Specimen adequacy assay controls in nucleic acid amplification tests do not correlate with nasopharyngeal swab collection method KHD Crawford, ML Baniecki, EG Dushin, CA Tierney, S Guan, ... Journal of Clinical Microbiology, e00975-24, 2024 | | 2024 |
| 361. Evaluation of Resistance to Nirmatrelvir/ritonavir in Evaluation of Protease Inhibition for COVID-19 (EPIC) High-Risk and Standard-Risk Clinical Trials M Lynn Baniecki, S Guan, Z Wang, Y Chen, W Bao, W He, E Dushin, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 431, 2023 | | 2023 |
| Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib C Charles-Schoeman, C Hyde, S Guan, N Parikh, J Wang, A Shahbazian, ... The Journal of Rheumatology 50 (12), 1573-1580, 2023 | | 2023 |
| A PHASE 1, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-AND MULTIPLE-DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06835375 … S Cohen, J Beebe, V Chindalore, S Guan, M Hassan-Zahraee, C Hyde, ... ANNALS OF THE RHEUMATIC DISEASES 82, 1450-1450, 2023 | | 2023 |
| Large‐scale profiling of physiologically relevant naturally occurring rare GPCR variants using the bioSensAll® technology F Cao, J Lau, A Gadzinski, C Normand, M Semache, A Mancini, MR Miller, ... The FASEB Journal 36, 2022 | | 2022 |
